First, we need to talk: mental healthcare in the MENA region
In our final installment of articles exploring mental health in emerging markets, we take an in-depth look at the situation in the MENA region
The Middle East and North Africa (MENA) faces daunting challenges in managing a growing burden of mental illness, often in adverse conditions that can leave their imprint on generations to come. While the burden of mental-health conditions is above the global average in most MENA countries, the human resources, policies, funding and infrastructure to deal with these problems are sorely lacking.
Good intentions, bad habits: Reforming mental healthcare in Latin America and the Caribbean
Published in eyeforpharma April 2018 by Marc Yates
The Latin America and Caribbean (LAC) region is a vast patchwork of countries, cultures and ethnicities, with a total population of more than 645 million, ranging from 209 million-plus in Brazil to islands with fewer than 100,000 inhabitants. The diversity is also economic. Recent years have seen marked improvements in income distribution and a burgeoning middle class, particularly in countries such as Argentina, Bolivia, Ecuador, Peru and Nicaragua. Yet Latin America and the Caribbean remains the region with the highest levels of income inequality worldwide. All of this has a significant bearing on the state of mental health in Latin America, where good intentions and genuine progress in reforming infrastructure and attitudes are clouded by treatment gaps, inadequate funding, over-centralisation, meagre human resources and persistent stigmatisation.
Out of the shadows: Mental health in the Asia Pacific region
Published in eyeforpharma February 2018 by Marc Yates
Mental health has been a peripheral issue in emerging markets for a long time, despite the severe impact it can have, not only on those directly affected but also on families, carers, social cohesion, and economic development. Fortunately, mental health is starting to get more attention, but there is still a widespread tendency to stigmatise and discriminate against people suffering with a mental illness. They are often considered as dangerous and aggressive which in turn increases the social distance.
Is there an opportunity for pharma to do more? In the first of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Asia where problems arising from ill mental health are the second largest contributor to years lost to disability (YL:D).